Related Experiment Video
Updated: Jan 17, 2026

Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
The Role of Pharmacogenomics in Optimizing Ketamine Therapy for Post-Amputation Pain
Alix Tappe1, Emily Burzynski1, Jhanvi Patel1
1Anesthesiology and Intensive Care Scientific Circle English Division (ANKONA ED), Medical University of Warsaw, 02-091 Warsaw, Poland.
Context And Objective:
Post-amputation pain (PAP) is an umbrella term that includes residual limb pain (RLP) and phantom limb pain (PLP), posing a significant challenge to recovery and quality of life after limb loss. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has gained interest for its potential to manage PAP, particularly in refractory cases. This narrative review explores the efficacy of ketamine for PAP and the emerging role of pharmacogenomics in guiding its use.
Methods:
A literature review of PubMed, Embase, and Cochrane databases was conducted, focusing on clinical trials, systematic reviews, and genetic influences on ketamine metabolism and response. Studies suggest that perioperative ketamine can reduce PAP severity and opioid use. However, outcomes vary, with some patients experiencing transient relief and others achieving prolonged benefit.
Results:
This variability may be linked to genetic differences in CYP2B6, CYP3A4/5, COMT Val158Met, SLC6A2, and KCNS1, which affect ketamine's metabolism, efficacy and side effect profile. Understanding these pharmacogenomic factors could enable more personalized and effective ketamine therapy.
Conclusion:
Despite its promise, inconsistent dosing regimens and limited integration of genetic data hinder standardization. Further research into genotype-guided ketamine protocols may improve treatment outcomes and support precision analgesia in amputee care.
Related Concept Videos
Parenteral Anesthetics: Overview
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Dosage Regimens: Partial Pharmacokinetic Parameters
Analgesia and Pain Management
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

